Hormone replacement therapy and breast cancer risk in California

Coombs, Nathan J., Taylor, Richard, Wilcken, Nicholas, Fiorica, James and Boyages, John (2005) Hormone replacement therapy and breast cancer risk in California. Breast Journal, 11 6: 410-415. doi:10.1111/j.1075-122X.2005.00132.x


Author Coombs, Nathan J.
Taylor, Richard
Wilcken, Nicholas
Fiorica, James
Boyages, John
Title Hormone replacement therapy and breast cancer risk in California
Journal name Breast Journal   Check publisher's open access policy
ISSN 1075-122X
1524-4741
Publication date 2005
Sub-type Article (original research)
DOI 10.1111/j.1075-122X.2005.00132.x
Volume 11
Issue 6
Start page 410
End page 415
Total pages 6
Place of publication Hoboken, NJ, United States
Publisher Wiley-Blackwell
Language eng
Subject 320000 Medical and Health Sciences
11 Medical and Health Sciences
1117 Public Health and Health Services
Abstract Numerous studies have documented increased breast cancer risks with hormone replacement therapy (HRT), but these do not give a woman her specific absolute risk for the remainder of her life. This article estimates the magnitude of the effect of HRT on breast cancer incidence in California and calculates a woman's cumulative risk of breast cancer with different formulations and durations of HRT use. The effects of HRT on the underlying breast cancer incidence were estimated using the attributable fraction method, applying HRT prevalence data from the 2001 California Health Interview Survey and published rates of higher relative risk (RR) from HRT use from the Women's Health Initiative (WHI) study and Million Women's Survey (MWS). The annual number of breast cancers potentially attributable to HRT in California was estimated, along with individual cumulative risk of breast cancer for various ages to 79 years according to HRT use, duration, and formulation. Using the WHI data, 829 of 19,000 breast cancers (4.3%) in California may be attributable to HRT This figure increases to 3401 (17.4%) when the MWS RRs are applied. Use of estrogen-only HRT or short-term (approximately 5 years) use of combined HRT has a minimal effect on the cumulative risk calculated to the age of 79 years; application of the MWS data to a Californian woman commencing HRT at the age of 50 years (no HRT, 8.5%; estrogen only, 8.6%; combined, 9.1%). Prolonged (approximately 10 years) use of combined HRT increases the cumulative risk to 10.3%. This article demonstrates that HRT will generate a small additional risk of breast cancer in an individual. The reduction in perimenopausal symptoms may be considered sufficient to warrant this extra risk. However, this view needs to be balanced because the small increases in individual risk will be magnified, producing a noticeable change in population cancer caseload where HRT use is high.
Keyword Oncology
Obstetrics & Gynecology
Breast Cancer
Estrogen
Hormone Replacement Therapy
Progesterone
Risk
Healthy Postmenopausal Women
Randomized Controlled-trial
Estrogen Plus Progestin
Q-Index Code C1
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 14 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 13 Aug 2007, 16:00:18 EST